<DOC>
	<DOCNO>NCT00537862</DOCNO>
	<brief_summary>This study evaluate efficacy safety enteric-coated mycophenolate sodium ( EC-MPS ) cyclosporine microemulsion base regimen C2 monitoring de novo kidney transplant recipient</brief_summary>
	<brief_title>Efficacy Safety Enteric-coated Mycophenolate Sodium ( EC-MPS ) Cyclosporine Microemulsion Based Regimen de Novo Living Donor Kidney Transplant Recipients</brief_title>
	<detailed_description />
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>Korean Males female age 18 65 year . Recipients first , live unrelated living relate nonHLA identical donor kidney Transplant , treat cyclosporine microemulsion ( CsME ) primary immunosuppressant . Females childbearing potential must negative serum pregnancy test within 7 day prior randomization . Effective contraception must use trial 6 week follow discontinuation study medication least four month randomization , even history infertility . Second subsequent kidney transplant multiorgan recipient ( e.g . kidney pancreas ) previous transplant organ . Kidneys cadaveric donor HLA identical living related donor . Patients know hypersensitivity enteric coat Mycophenolate sodium ( ECMPS ) component formulation ( e.g . lactose ) . Patients thrombocytopenia ( &lt; 75,000/mm3 ) , absolute neutrophil count &lt; 1,500/mm3 , and/or leukocytopenia ( &lt; 4,000/mm3 ) , hemoglobin &lt; 6g/dL . Patients receive investigational drug within 30 day prior study entry . Patients history malignancy within last five year , except successfully excise squamous basal cell carcinoma skin . Females childbearing potential planning become pregnant , pregnant and/or lactating , unwilling use effective mean contraception . Existence surgical medical condition , current transplant , opinion investigator might significantly alter absorption , distribution , metabolism excretion study medication , and/or presence severe diarrhea , active peptic ulcer disease , uncontrolled diabetes mellitus . Patients clinically significant infection require continue therapy . Known positive HIV status . Positive HBsAg test , Hepatitis C positive advance liver disease clinical pathological diagnosis cirrhosis . Evidence drug and/or alcohol abuse Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Kidney Transplant Patients</keyword>
	<keyword>Immunosuppresion</keyword>
	<keyword>Enteric-coated mycophenolate sodium</keyword>
</DOC>